Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Acıbadem Labcell | OTHER |
Not provided
Not provided
Not provided
Not provided
Pathogen-free, concentrated, pooled convalescent plasma has higher SARS-CoV2 antibody titers and neutralizing antibody activities, without requiring blood group compatibility that allows patient accessibility in a shorter time and has safe plasma characteristic.
The efficacy of SARS-CoV2 standard single donor convalescent plasma varied according to the application time and most importantly the amount of antibody that is administered. Single donor plasma has some drawbacks; such as the insufficient levels of neutralizing antibody activities, the requirements of blood group compatibility, and the risk of infection transmission. In this study, the efficacy and safety of pathogen inactivated, isohemagglutinin-depleted (concentrated) and pooled convalescent plasma was investigated.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single donor convalescent plasma | Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with single donor plasma | ||
| ACB- IP 1.0 | Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with ACB- IP 1.0 pathogen-free concentrated cocktail convalescent plasma |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Mortality Rate | A mortality rate is a measure of the frequency of occurrence of death in a defined population during a specified interval. | 6 Months |
| Length of Hospitalization | The average length of stay in hospitals (ALOS) is often used as an indicator of efficiency | 6 Months |
| Measure | Description | Time Frame |
|---|---|---|
| Side Effects | Problems that occur when treatment goes beyond the desired effect. Or problems that occur in addition to the desired therapeutic effect. | 6 Months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adults with positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and/or radiologically confirmed pneumonia, were included in the study.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ercument Ovalı, MD | Contact | +905325729174 | ercument.ovali@acibadem.com | |
| Cansu Hemsinlioglu | Contact | +905356782771 | chemsinlioglu@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Acıbadem Labcell Cellular Therapy Laboratories | Recruiting | Istanbul | 34758 | Turkey (Türkiye) |
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| Acibadem Altunizade Hospital | Recruiting | Istanbul | Turkey (Türkiye) |
|
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |